Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 15/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1242769 | 0.93 | KCNA5 (0.73) | KCNA5KCNH2 | |
| SCHEMBL1242052 | 0.91 | KCNA5 (0.57) | KCNA5KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1243224 | 0.88 | KCNA5 (0.69) | KCNA5KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1242850 | 0.87 | KCNA5 (0.52) | KCNA5KCNH2CYP3A4NPSR1 | |
| SCHEMBL1242195 | 0.82 | KCNA5 (0.47) | KCNA5KCNH2 | |
| SCHEMBL1242084 | 0.82 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1243446 | 0.82 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1242118 | 0.81 | KCNA5 (0.70) | KCNA5KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1243383 | 0.81 | KCNA5 (0.70) | KCNA5KCNH2 | |
| SCHEMBL1243260 | 0.81 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781635-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | KCNA5 11/4885KCNH2 3/4885CYP3A4 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.